Characterization of lipooligosaccharides from Haemophilus ducreyi containing polylactosamine repeats  by Schilling, Birgit et al.
Characterization of Lipooligosaccharides
from Haemophilus ducreyi Containing
Polylactosamine Repeats
Birgit Schilling and Bradford W. Gibson*
Buck Institute for Age Research, Novato, California, USA
Melanie Filiatrault and Anthony A. Campagnari
Infectious Disease Institute, State University of New York, Buffalo, New York, USA
Haemophilus ducreyi, a gram-negative human mucosal pathogen, is one of the principal causes
of genital ulcer disease. The lipooligosaccharides (LOS) of these bacteria are considered to be
a major virulence factor and have been implicated in the adherence and invasion of H. ducreyi
to several human cell types. An isogenic heptosyltransferase-III knockout strain (waaQ) was
recently constructed from H. ducreyi 35000 wild-type strain and immunochemical and
molecular weight data of the isolated LOS suggested the presence of poly-N-acetyllactosamine
(LacNAc) (Filiatrault et al., Infect. Immun. 2000, 68, 3352–3361). In this present study, the
structures of these novel LOS-glycoforms were characterized by matrix-assisted laser desorp-
tion/ionization (MALDI) and electrospray ionization (ESI) mass spectrometry in combination
with exoglycosidase digestion. Detailed structural information was obtained for the oligosac-
charide (OS) portions of these LOS showing between one to five linear LacNAc repeats on the
non-reducing terminus of the main oligosaccharide branch. When grown on solid media, the
organism produced LacNAc repeats that were further modified by the addition of sialic acid.
Enzymatic digestion with -galactosidase, -N-acetylhexosaminidase, and neuraminidase
type VI-A yielded truncated glycoforms consistent with a polyLacNAc structure capped at
various end points with sialic acid. ESI-MS/MS mass spectrometry on a quadrupole time-of-
flight instrument was particularly effective in obtaining detailed structural information on the
least abundant, high-mass glycoforms. Although LOS containing terminal di-LacNAc have
been reported, this is the first time to our knowledge that a linear polyLacNAc structure has
been characterized in bacteria. (J Am Soc Mass Spectrom 2002, 13, 724–734) © 2002 American
Society for Mass Spectrometry
Haemophilus ducreyi is a gram-negative bacteriumwhich causes genital ulcer disease or chan-croid. Although chancroid is uncommon in the
United States, it is prevalent in many developing coun-
tries worldwide [1]. Chancroid has also been shown to
be a significant risk factor for transmission of human
immunodeficiency virus (HIV) [2–4]. Recently, the
number of H. ducreyi clinical isolates with antibiotic
resistance has increased [1, 5], suggesting that this
sexually transmitted disease is far from contained and
represents a growing threat to world health.
Although several outer-membrane or secreted com-
ponents of H. ducreyi have been suggested as contrib-
uting to the pathogenesis and virulence of this organ-
ism, our laboratory has investigated the structures and
possible functions of outer-membrane lipooligosaccha-
ride (LOS). LOS is considered to be a major virulence
factor and has been implicated as a cytotoxin [6] as well
as contributing in the adherence and invasion of H.
ducreyi to cultured human foreskin fibroblasts and
keratinocytes [7, 8]. Structures of major LOS-glycoforms
from several wild type strains have been identified and
shown to contain terminal epitopes that mimic human
glycoconjugates [9–12]. As shown in Figure 1, bacterial
lipooligosaccharides consist of a Lipid A and oligosac-
charide moiety, the latter containing a conserved oligo-
saccharide core region that is substituted with one or
more oligosaccharide branches. The major LOS-glyco-
form from the prototype H. ducreyi 35000 strain has
been shown by NMR and mass spectrometry to contain
a terminal N-acetyllactosamine (LacNAc) disaccharide,
Gal13 4GlcNAc1, that is partially modified by the
addition of sialic acid (N-acetylneuraminic acid, or
NeuAc) to form NeuAc23 3Gal13 4GlcNAc [11,
13]. In addition, Melaugh et al. [10] reported that a
di-LacNAc glycoform was also present at very low
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abundances in strain 35000. A similar observation was
reported by Schweda et al. [14] for several clinical
isolates. The di-LacNAc pathway appears to compete
with a more dominant biosynthetic pathway that adds
sialic acid, effectively capping the extension of the
oligosaccharide branch [10]. Although a di-LacNAc
structure has also been suggested to be present in the
related mucosal pathogen Neisseria gonorrhoeae [15],
little structural evidence has been presented other than
molecular mass to support these assignments, in part
due to the very low abundance of these extended
LOS-glycoforms under in vitro growth conditions.
Moreover, to the best of our knowledge, there have
been no reports of LacNAc structures extended beyond
two repeats to form polylactosamine (polyLacNAc)
LOS-glycoforms in bacteria despite numerous reports
of analogous structures in eukaryotes [16–18].
Over the past five years, several LOS-specific glyco-
syltransferases have been identified and gene knockout
mutants constructed from the prototype H. ducreyi
wild-type strain 35000. To verify the specificity of these
glycosyltransferases, structural studies of the resulting
altered LOS-glycoforms have been carried out [13, 19].
In a recent study, an isogenic heptosyltransferase-III
knockout strain (35000hep) was constructed by Fili-
atrault et al. [20] in which immunochemical and molec-
ular mass data suggested the presence of several un-
usual structural features. Specifically, a series of high
molecular weight glycoforms (Mr  3000) were ob-
served by SDS-PAGE which reacted with a monoclonal
antibody (3F11) that recognizes LOS containing termi-
nal LacNAc or paragloboside [21]. Moreover, the
masses of the glycoforms as determined by MALDI-MS
indicated that these glycoforms were formed by
mutiple additions of alternating Hex and HexNAc
residues, consistent with a polyLacNAc structure. To
provide structural support for these tentative assign-
ments, we have carried out an extensive characteriza-
tion of these novel LOS-glycoforms using a combina-
tion of mass spectrometric methods (MS and MS/MS)
and exoglycosidase digestion with -galactosidase,
-N-acetylhexosaminidase, and neuraminidase type
VI-A. These data now show that these high molecular
weight LOS-glycoforms contain up to five repeating
LacNAc units on a single oligosaccharide branch that
can also undergo substitution with sialic acid under
solid phase growth conditions.
Experimental
Materials
N-Acetylneuraminic acid was obtained from Sigma (St.
Louis, MO). GC Medium Base, brain heart infusion, and
hemoglobin were obtained from DIFCO (Detroit, MI);
inactivated fetal bovine serum (FBS) was obtained from
the Cell Culture Facility at UCSF; IsoVitaleX was pur-
chased from Becton Dickinson (Franklin Lakes, N.J.).
All reagents used in chemical reactions were obtained
from commercial suppliers and used without further
purification unless otherwise noted.
Methods
Bacterial strains and culture conditions. H. ducreyi strains
were cultured at 35 °C in 5% CO2 on chocolate agar
plates or in brain heart infusion broth as previously
described [22]. When needed, chocolate agar plates
were supplemented with Kanamycin (20 g/ml), chlor-
amphenicol (1 g/ml), and/or 5-bromo-4-chloro-3-in-
dolyl--D-galactopyranoside (X-Gal; 40 g/ml). The
construction of these isogenic mutants was previously
described [20].
Preparation of LOS. LOS from proteinase K-treated
whole-cell lysates was resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
on a 14% acrylamide gel and visualized by silver
staining [22, 23]. Western blot analysis was performed
by transferring LOS to a PVDF membrane (Millipore,
Bedford, MA) using a previously described procedure
[24]. LOS for structural analysis was extracted by using
the modified hot phenol-water procedure from bacteria
that were grown overnight in 1.6 L of broth and dried
[25–27]. In each case, approximately 0.5–1.0 mg of LOS
was converted to the O-deacylated LOS-glycoforms by
treatment with hydrazine (37 °C, 30 min) [28], a process
that increases solubility and makes the LOS more
amenable to mass spectrometric analysis [9]. In addi-
tion, a portion of the O-deacylated LOS was further
Figure 1. Bacterial lipooligosaccharides contain a Lipid A and an oligosaccharide moiety which
includes a conserved oligosaccharide core and one or more oligosaccharide branches added to the core
structure. The major LOS-glycoform from the prototype H. ducreyi 35000 strain contains a terminal
N-acetyllactosamine (LacNAc) disaccharide, Gal13 4GlcNAc1, that is partially modified by the
addition of sialic acid.
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treated with 48% aqueous hydrofluoric acid (HF) (at
4 °C for 12 h) to remove phosphoethanolamine (PEA)
and phosphate (P) groups [10]. Finally, an oligosaccha-
ride fraction of strain 35000hep (broth) was prepared
by hydrolysis of the crude LOS (0.5–1.0 mg) in a
solution of 1% acetic acid (350 l) at 100 °C for 2 h [10].
The oligosaccharide fractions were then separated from
the Lipid A fraction by centrifugation (5000  g, 4 °C)
and purified by size exclusion chromatography using
two 300  7.8 mm BioSelect SEC 125–5 columns (Bio-
Rad) connected in series. Samples were eluted in 50 mM
pyridinium acetate (pH 5.2) at a flow rate of 1 mL min1
and collected in 0.5–1 mL fractions. Alternatively, an
oligosaccharide fraction was prepared from strain
35000hep (plate) under milder conditions that retains
terminal sialic acid residues. This method consisted of
hydrolyzing the O-deacylated LOS in a 100 mM ammo-
nium acetate solution (pH 4.5) at 80 °C for 1 h. The
crude reaction mixture was then directly analyzed by
mass spectrometry.
Exoglycosidase digestion. To determine the identity and
linkages of terminal sugars in these LOS preparations,
O-deacylated LOS was subjected to treatment with
specific exoglycosidases and re-analyzed by MALDI-
MS. Exo-glycosidases used were -galactosidase from
Jack bean meal (-Galase, highly specific for cleavage of
-anomeric glycosidic bonds; hydrolysis of 1–6 and
1–4 linked Gal-GlcNAc clearly favored over the cor-
responding 1–3 bonds with relative hydrolysis rates,
100:75:1, respectively), -N-acetylhexosaminidase from
Jack bean meal (-HexNase, highly specific for cleavage
of -anomeric glycosidic bonds such as 1–2,3,4 and 6
linked GlcNAc and GalNAc residues), and/or neur-
aminidase type VI-A from Clostridium perfringens at-
tached to beaded agarose (NANase, specific for cleav-
age of terminal NeuAc). -galactosidase and -N-
acetylhexosaminidase were purchased from Oxford
GlycoScience (Oxford, UK), neuraminidase was pur-
chased from Sigma (St. Louis, MO). Approximately 10
g of O-deacylated LOS was dissolved in 25 l of 50
mM ammonium acetate buffer (pH 4.5). Digestions with
alternating enzymes were performed sequentially [15].
For each digestion step, O-LOS were incubated at 37 °C
for 24 h using -galactosidase (0.8 units/ml) or -N-
acetylhexosaminidase (50 units/ml), respectively,
whereas a shorter incubation time was chosen for
neuraminidase treatment (37 °C for 3 h, 2 units/ml).
Each digestion step was terminated after completion by
heating the reaction mixture for 2 min at 100 °C to
deactivate the enzyme. An aliquot was taken for MS
analysis and subsequently an alternating enzyme was
added and the reaction was incubated.
Matrix-assisted laser desorption/ionization mass spectro-
metry. The O-deacylated LOS, HF-treated O-deacy-
lated LOS, and acid released oligosaccharide fractions
from the mutant and parental 35000 strain were all
analyzed by MALDI-MS. An Applied Biosystems (Fra-
mingham, MA) Voyager DE or a Voyager DESTR
time-of-flight mass spectrometer were used to analyze
the various LOS preparations as previously described
[9]. Mass spectra were run in both the positive- and
negative-ion mode and under post-source decay condi-
tions (PSD) [29]. Both instruments were equipped with
a nitrogen laser (337 nm) and operated under delayed
extraction conditions [30]; delay time was 100–175 ns,
grid voltage was 92–94% (linear mode) and 70–75%
(reflectron mode), respectively, of full acceleration volt-
age (20–30 kV). In PSD mode, precursor ions were
selected by timed-ion selection and the resulting frag-
mentation products were focused by adjusting the
reflectron voltage in 9–11 steps. The acquired segment
spectra were then stitched together to obtain the com-
posite PSD spectrum; PSD spectra were smoothed using
a Gaussian algorithm causing fragment ions to appear
as average masses. Samples were purified and desalted
by drop dialysis using a 0.025 m nitrocellulose mem-
brane and/or by anion exchange Zip TipsAX (Millipore).
Approximately 0.1–0.2 g of O-deacylated LOS was
mixed with 1 l of a 320 mM 2,5-dihydroxybenzoic acid
(DHB) in 4:1 acetone/water (vol/vol) containing 175
mM 1-hydroxyisoquinoline (HIC) [31], desalted with
cation-exchange resin beads (DOWEX, 50X, NH4
) and
then air dried on a stainless steel target. Spectra were
acquired, averaged and mass calibrated with an exter-
nal calibrant consisting of an equimolar mixture of
angiotensin II, bradykinin, LHRH, bombesin, -MSH
(CZE mixture, Bio-Rad) and ACTH 1–24 (Sigma, St.
Louis, MO). Typically, 20–50 laser shots were used to
record each linear spectrum, or spectral segment if PSD
conditions were used.
Electrospray Ionization Mass Spectrometry. Oligosaccha-
rides and HF-treated O-deacylated LOS were further
analyzed in positive-ion mode on a quadrupole orthog-
onal time-of-flight mass spectrometer (QSTAR, PE
Sciex, Concorde, Canada). Samples were dissolved in a
1:1 solution of 100 mM NH4OAc (pH 4.5) and acetoni-
trile and loaded into a Protana nanospray tip. The
nanospray needle voltage was typically 1200–1300 V.
Mass spectra (ESI-MS) and tandem mass spectra (ESI-
MS/MS) of O-deacylated LOS and of HF-treated O-
deacylated LOS were recorded in positive-ion mode. In
MS mode a resolution of 12,000–15,000 FWHM was
achieved, which allowed unambiguous determination
of the charge state. For collision induced dissociation
(CID) MSMS, the mass window for precursor ion selec-
tion of the quadrupole mass analyzer was generally set
to  1 m/z. The selected ions were fragmented in a
collision cell using air as collision gas and analyzed in
the orthogonal TOF operating at an acceleration poten-
tial of 4 kV. Spectra were calibrated using MS/MS
fragment-ions of a glufibrino peptide standard
(EGVNDNEEGFFSAR, m/z at 187.0719 [B2-ion], and m/z
at 1285.4995 [Y11-ion]) providing a mass accuracy of
50 ppm.
726 SCHILLING ET AL. J Am Soc Mass Spectrom 2002, 13, 724–734
Results and Discussion
The lipooligosaccharides from the isogenic waaQ mu-
tant which is deficient in the heptosyltransferase-III
(35000hep) and its parental strain 35000 were ana-
lyzed by SDS-PAGE and Western blotting (Figure 2).
The LOS from a previously characterized mutant
(HD35000R) that synthesizes a highly truncated LOS
that lack a terminal LacNAc structure [20] was also
analyzed as negative control. The migration pattern of
wild-type 35000 (lane 1a) and mutant 35000hep (lane
3a) appeared to be similar, but 35000hep showed one
new band with a higher molecular weight. Western blot
analysis of this same gel with MAb 3F11, an antibody
that recognizes terminal LacNAc, showed immunore-
activity with two prominent bands in the LOS from the
mutant strain 35000hep, suggesting the presence of
LOS containing mono-LacNAc and di-LacNAc glyco-
forms (lane 3b). Closer inspection revealed that the
35000 wild-type LOS also contained some correspond-
ing higher mass glycoforms, but only as a very minor
components (lane 1b).
Mass spectrometric analysis of the O-deacylated LOS
of the 35000hep mutant confirmed loss of one core
heptose residue compared to the wild-type strain 35000
as expected from the disruption of heptosyltransferase-
III gene. MALDI-MS spectra of O-LOS isolated from
strain 35000hep grown in liquid broth media (Figure
3a) showed LOS-glycoforms that were shifted down in
mass by 192 Da, the residue mass for heptose. The
deprotonated molecular ion peaks [MH] at m/z 2518.3
and 2641.5 correspond to the major wild-type glycoforms
terminating in LacNAc, i.e., Gal3GlcNAc3
Gal3 Hep3 Glc3 Hep23 KdoP(PEA)0,1 – O-deacyl-
Lipid A, which is now lacking the terminal core hep-
tose-III residue (referred to as A'5 according to the
nomenclature by Bozue et al. [13]). The amount of PEA
substituted on LOS is variable, as evident from the
expected mass shifts of 123 Da. The peaks at m/z 2356.2
and 2479.3 (A'4) appear to arise from the additional loss
of the terminal galactose, a minor branch structure also
seen in the wild-type LOS structure (data not shown).
However, in addition to these expected LOS-glyco-
forms, several new high mass LOS species were ob-
served that suggested other modifications to these LOS
in addition to the loss of heptose. For example, LOS
species terminating in LacNAc did not appear to be
sialylated, unlike the parental wild-type strain in which
this is the second most abundant glycoform, i.e.,
NeuAc23 3Gal13 4GlcNAc-R [10, 11]. Rather, sev-
eral high mass LOS-glycoforms were present whose
masses were consistent with the extension of a second
Figure 2. A composite of a silver stained SDS-PAGE gel (panel a)
and the corresponding Western Blot (panel b). The gel contains
LOS from H. ducreyi wild-type strain 35000 (lane 1), double
knockout mutant strain HD35000R (lane 2), and heptosyltrans-
ferase knockout mutant 35000hep (lane 3). For Western staining
the monoclonal antibody 3F11 was used. This antibody which was
originally generated against LOS from N. gonorrhoeae has specific-
ity for terminal LacNAc.
Figure 3. Negative-ion MALDI-TOF mass spectra of O-deacy-
lated LOS from heptosyltransferase knockout mutant strain
35000hep. (a) 35000hep grown in liquid media (broth), and (b)
35000hep grown on solid media (plate). Bold labels indicate
sialylated species. Spectra were recorded in linear mode yielding
average masses.
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LacNAc moiety at m/z 2883.7 and 3006.9 (A'5b2, mass
difference is variable PEA substitution). Further addi-
tions of N-acetylhexosamine (i.e., GlcNAc) and hexose
(i.e., Gal) to this abundant di-LacNAc structure can be
seen as leading to the formation of relatively minor
LOS-glycoforms containing as many as five LacNAc
repeats, i.e, m/z 3086.7, 3248.7, 3452.5, 3614.3, 3817.2,
3979.7 (A'5b3,. . ., A'5b8, respectively). If these higher
mass glycoforms contain linear repeats of LacNAc, LOS
structures can be depicted as shown in Figure 4, where
the mass values listed are those calculated for the
average masses and are in agreement with those ob-
served in the corresponding MALDI-MS spectra (Figure
3a). The average molecular masses of the O-deacylated
LOS-glycoforms are also summarized in Table 1. Al-
though the LOS containing the terminal di-LacNAc was
detectable on SDS-PAGE (Figure 2, lane 3), the glyco-
forms containing polyLacNAc were only visible in gels
that were severely overloaded (data not shown).
Unexpectedly, bacteria of the same mutant strain
35000hep grown on plates (i.e., solid media) expressed
a somewhat different set of high mass LOS-glycoforms
as can be seen in the corresponding MALDI-MS spec-
trum (see Figure 3b). As mentioned above, mutant
organisms grown in broth expressed glycoforms con-
taining mono- (A'5) and di-LacNAc (A'5b2), as well as
less abundant LOS containing polyLacNAc extensions
(A'5b3,. . .,A'5b8). In contrast, when this same organism
is grown on solid media, a series of major LOS-glyco-
forms terminating in either a single LacNAc (A'5, m/z at
2518.1 and 2641.2) or two LacNAc repeats (A'5b2, m/z at
2883.7 and 3006.9) were observed. Moreover, both the
mono- and di-LacNAc LOS-glycoforms were partially
sialylated, producing structures terminating in
NeuAc23 3Gal13 4GlcNAc (A'5a1, m/z at 2809.4
and 2932.3) and in NeuAc23 3(Gal13 4GlcNAc)2
(A'5b2a1, m/z at 3174.7 and 3297.2), but with no further
extensions (these structures are also depicted in Fig-
Figure 4. Structures and average masses [M-H] for the various O-deacylated LOS-glycoforms from
35000hep mutants grown on (a) broth and (b) plates. Nomenclature for LOS-glycoform structure is
based on the nomenclature of Bozue et al. [13], for H. ducreyi LOS-glycoforms, where A'n refer to the
major oligosaccharide branch structures substituted on Hep-I of the conserved Hep2Kdo-Lipid A* core
that lacks Hep-III. The normal position of the missing Hep-III from the LOS obtained from 35000hep
is drawn in a crossed out box. All core heptoses are L-glycero-D-manno-heptose with the exception of
the branch heptose (labeled with an asterisk) which is D-glycero-D-manno-heptose. Lipid A* refers to
the di-N-acyl-diphosphoryl form generated after hydrazine treatment.
Table 1. Molecular masses and proposed compositions of
O-deacylated LOS from H. ducreyi strain 35000hep-
(LacNAc)n-R
a
n  Mr (obs.)
b Mr (calc.)
c M (ppm)
0  GlcNAc 2357.16 2357.14 9
0  GlcNAc 2480.26 2480.19 28
1 2519.31 2519.28 12
1 2642.46 2642.33 49
1  GlcNAc 2722.66 2722.48 12
1  GlcNAc 2845.66 2845.52 49
2 2884.71 2884.62 31
2 3007.89 3007.66 76
2  GlcNAc 3087.67 3087.81 45
3 3249.74 3249.96 68
3  GlcNAc 3453.51 3453.15 104
4 3615.33 3615.29 11
4  GlcNAc 3818.23 3818.49 68
5 3980.66 3980.63 8
1  NeuAc 2810.39 2810.54 53
1  NeuAc 2933.35 2933.59 82
2  NeuAc 3175.69 3175.88 60
2  NeuAc 3298.62 3298.93 94
aNumber n refers to repeating LacNAc moieties substituted on the
remaining LOS structure, i.e., R  Gal-Hep-Glc-Hep2(PEA)0-1-Kdo-Lipid
A*, where Lipid A* is the di-N-acyl-diphosphoryl form
bAll experimental data was obtained by negative-ion MALDI-MS yield-
ing [M  H] ions (average masses) as shown in Figure 2.
cAll calculated masses are expressed as average masses.
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ure 4 and their corresponding compositions listed in
Table 1).
To better characterize these novel high molecular
weight structures (i.e., polyLacNAc LOS), a series of
stepwise enzymatic digestions were employed using
various combinations of -galactosidase, -N-acetyl-
hexosaminidase, and neuraminidase. In one experimen-
tal regimen, the original LOS mixture obtained from
organisms grown in broth was first treated with -ga-
lactosidase, followed by successive treatments of -N-
acetylhexosaminidase, -galactosidase, and -N-acetyl-
hexosaminidase (see Figure 5a). In this experiment, one
expects a downward shift in mass in increments of 162
Da for loss of terminal -linked galactose and 203 Da for
loss of terminal -linked HexNAc (GlcNAc). Although
these high mass LOS-glycoforms were of relative low
abundances, one can clearly see the appearance (and/or
disappearance) of various molecular ions that can be
interpreted as the successive losses of one sugar (Gal or
HexNAc) per digestion step for the majority of LOS-
glycoforms. These mass shifts are consistent with a
linear polyLacNAc structure as originally suggested by
the immunochemical data (Figure 2).
To examine LOS containing sialic acid (Figure 5b and
c), neuraminidase was added to the exoglycosidase
treatment regimen. As discussed above, there was evi-
dence that the mutant strain 35000hep grown on
plates synthesized abundant sialyl-LacNAc and sialyl-
di-LacNAc LOS species. To test this hypothesis, O-LOS
prepared from plate-grown organisms was sequentially
incubated with neuraminidase (m  291 Da), -galac-
tosidase and -N-acetylhexosaminidase (Figure 5b). Al-
ternatively, these same O-LOS were treated with -ga-
lactosidase, followed by -N-acetylhexosaminidase and
then neuraminidase (Figure 5c). Molecular ions at m/z
2809.4/2932.3 (A'5a1) and at m/z at 3174.7/3297.2
(A'5b2a1) were easily identified as sialylated glycoforms
by their susceptibility to neuraminidase treatment, but
they were resistant to prior treatment with -galactosi-
dase or N-acetylhexosaminidase. In addition, these data
are consistant with LOS structures where LacNAc
serves as the acceptor for sialic acid.
To confirm that these high molecular weight LOS-
glycoforms containing polyLacNAc and sialylated Lac-
NAc structures emanate from a single oligosaccharide
branch, series of tandem mass spectrometry were per-
formed on various LOS preparations. MALDI post-
source decay (PSD) and ESI tandem mass spectrometry
(ESI-MS/MS) were used to establish the overall archi-
tecture and branching pattern of these structures. Using
MALDI-PSD, several molecular ions were individually
selected and their metastable decomposition fragments
were detected by the reflectron mass analyzer. As
shown in Figure 6, MALDI-PSD spectra from O-deacy-
lated LOS species with [M  H] at m/z 3006.7 (Figure
6a), m/z 2883.7 (Figure 6b), and m/z 2721.7 (Figure 6c)
were recorded in the negative-ion mode and provided
limited structural information on the oligosaccharide
(and Lipid A) portion of the LOS. For example, at high
mass the MALDI-PSD spectrum of the O-LOS at m/z
3006.7 showed loss of PEA and -elimination of phos-
phoric acid (H3PO4, m  98 Da) whereas the
MALDI-PSD spectra of O-LOS at m/z 2883.7 and 2721.7
showed a loss of phosphate only. At lower masses,
Figure 5. Negative-ion MALDI-TOF mass spectra of O-deacylated LOS mutant strain 35000hep
before and after exogycosidase digestion as follows: (a) Bacteria grown in broth. From top to bottom,
O-LOS untreated and then treated in succession with -galactosidase, -N-acetylhexosaminidase,
-galactosidase, and -N-acetylhexosaminidase; (b) Bacteria grown on plates. From top to bottom,
O-LOS untreated and treated in succession with neuraminidase, -galactosidase, and -N-acetylhex-
osaminidase; (c) Bacteria grown on plates. From top to bottom, O-LOS untreated and treated in
succession with -galactosidase, -N-acetylhexosaminidase, and neuraminidase. Spectra were re-
corded in linear mode yielding average masses.
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fragments are seen for the corresponding di-N-acyl
diphosphoryl Lipid A (m/z 952) and oligosaccharide
moieties by cleavage of the labile Kdo-O-Lipid A gly-
cosidic bond [9]. The oligosaccharide moieties undergo
further fragmentation including the loss of CO2 from
Kdo (44 Da), PEA (123 Da), phosphoric acid (98
Da), and H2O (18 Da). The molecular ions at m/z
3006.7 and 2883.7 were both assigned as di-LacNAc
containing glycoforms (A'5b2) containing either one or
no PEA. The major oligosaccharide fragments at m/z
2053.9/2009.9 (Figure 6a) and m/z 1930.9/1886.9 (Figure
6b) differed by 123 Da, confirming that PEA heteroge-
neity is present on the oligosaccharide rather than the
Lipid A moiety. The MALDI-PSD spectrum of molecu-
lar ion at m/z 2721.7 (A'5b1) yielded oligosaccharide
fragments at m/z 1768.9 and 1724.7 that can be assigned
as oligosaccharide moiety containing no PEA and lack-
ing a single galactose extension from a terminal mono-
LacNAc species (1930.9-162 Da). However, no fragmen-
tation was observed in these PSD spectra that revealed
sequence information of the oligosaccharide.
To obtain more detailed information of the oligosac-
charide moiety, the LOS-glycoforms were cleaved by
acid treatment and separated from the Lipid A by
centrifugation and size exclusion chromatography. It
should be noted that hydrolysis of LOS also results in
the -elimination of phosphate and phosphorylphos-
phoethanolamine (PPEA) from Kdo forming anhydro-
Kdo at the reducing terminus [10, 32]. The exact masses
of the released oligosaccharides with up to five lac-
tosamine units were determined by ESI-MS in positive
ionization mode and are summarized in Table 2. For
most oligosaccharides, mass accuracies 20 ppm could
be achieved using the previously well characterized
glycoforms (A'5 and A'5b1) as internal standards; oligo-
saccharides containing four and five LacNAc units were
externally calibrated. Sialylated LOS that were isolated
from bacteria grown on plates had to be hydrolyzed
using a milder method to retain the sialic acid residue.
The latter oligosaccharides were subsequently analyzed
by MALDI-MS in linear, negative-ion mode yielding
molecular ion peaks [MH] at m/z 1485.3 (A'5), 1689.0
(A'5b1), 1850.2 (A'5b2), and the sialylated species at m/z
1776.4 (A'5a1) and 2141.6 (A'5b2a1).
As previously reported [33, 34], MALDI-PSD can be
used to obtain sequence information of carbohydrates.
MALDI-PSD spectra recorded for two such oligosaccha-
rides as shown in Figure 7 where the sodium adducts
[M  Na] at m/z 1874.0 and 2604.8 contain either two
or four terminal LacNAc structures, respectively. For
the di-LacNAc oligosaccharide, a series of sequence-
ions was generated that correspond to cleavage of the
carbohydrate chain, including a Y-ion (m/z 1509.2,
1346.9, 1143.7, and 981.3), B-ion (m/z 1653.9, 1461.8,
1269.4, 1107.9, 915.9, 753.5, and 388.6) and correspond-
ing C-ion series (see inset, Figure 7a). The most abun-
dant fragment-ion at m/z 1653.9 was assigned to a B8-ion
as a simple loss of Kdo from the reducing terminus. A
few fragment-ions were observed that result from two
or more cleavages (internal fragments), such as further
loss of Kdo from Y5-ion (m/z 923.8, internal fragment).
In addition, a MALDI-PSD spectrum of a polyLacNAc-
containing oligosaccharide with four repeats was re-
corded (Figure 7b). In the original unseparated O-LOS
mixture from which this oligosaccharide was obtained,
the corresponding glycoform was only observed as a
minor component (i.e., O-deacylated LOS at m/z 3614.3,
Figure 3a). Despite its weak signal and the large de-
crease in the abundance of fragments, the MALDI-PSD
spectrum yielded B-type fragment ions at m/z 388.0,
550.2, 753.7, 1118.3, 1484.0, 1645.8, and 1837.7 that were
consistent with a linear (LacNAc)4 structure as shown
in Figure 6c.
Figure 6. Negative-ion MALDI-PSD spectrum of O-deacylated
LOS selecting deprotonated precursor ion (a) [M  H] at m/z
3006.7 (A'5b2*, with 1 PEA and 2 LacNAc); (b) [M  H]
 at m/z
2883.7 (A'5b2, with 0 PEA and di-LacNAc structure), and (c) [M 
H] at m/z2721.7 (A'5b1, with 0 PEA and terminal GlcNAc-Gal-
GlcNAc structure).
Table 2. Molecular masses of oligosaccharides containing 1 to
5 LacNAc units prepared from H. ducreyi strain 3500hep-
# LacNAca Mr (obs.)
b Mr (calc.) M [ppm]
1 1485.493 1485.486 4
1  GlcNAc 1688.544 1688.566 13
2 1850.616 1850.619 1
2  GlcNAc 2053.704 2053.698 3
3 2215.709 2215.751 19
3  GlcNAc 2418.816 2418.830 6
4 2580.776 2580.883 41
4  GlcNAc n.d. - -
5 2945.860 2946.015 53
aNumbers refer to repeating LacNAc moieties substituted on the con-
served Gal-Hep-Glc-Hep2(PEA)0-1-anhydroKdo oligosaccharide portion
of the LOS. At the reducing terminus, anhydroKdo oligosaccharide
portion of the LOS. At the reducing terminus, anhydroKdo is formed by
-elimination of phosphate (P) or pyrophospho-ethanolamine (PPEA)
under acid conditions [9].
bAll masses were recorded by ESI-MS in positive-ion mode yielding
12[C]-containing isotopic masses.
cPreviously well characterized glycoforms A'5 and A'5b1 were used as
internal calibration standards.
nd glycoform was not detected.
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MALDI-PSD characterization of these LOS species,
either as free oligosaccharides or O-LOS, became prob-
lematic as one progressed to higher mass or to LOS-
glycoforms that contained sialic acid. To see if ESI
MS/MS might yield more complete sequences for these
glycoforms, we investigated both O-LOS and free oli-
gosaccharides (in mixtures) using a high performance
quadrupole time-of-flight instrument. Under ESI condi-
tions, free oligosaccharides form both doubly and triply
charged molecular ions. For some oligosaccharides,
only molecular ion species containing one or more
cations were observed, e.g., [M  2H  Na]3 and
[M  2H  K]3. Metal ions such as Na and K are
likely introduced into the samples from the coated
nanoelectrospray needles. However, as has been re-
ported by others [35], oligosaccharides that are partially
metalated can sometimes undergo more extensive frag-
mentation. ESI MS/MS experiments on oligosaccha-
rides containing di- to penta-LacNAc moieties, as well
as some sialylated counterparts, were therefore carried
out on various cationated molecular ions.
ESI-MS/MS spectra of the oligosaccharide contain-
ing di-LacNAc (A'5b2, M  1850.6) were obtained by
selecting a doubly charged sodiated precursor ion,
[M  H  Na]2 at m/z 937.32 as well as the doubly
charged potassium precursor ion, [MH K]2 at m/z
945.32 (Figure 8). Most fragment-ions were singly
charged Y- and B-ion fragments and were analogous to
those observed in the MALDI-PSD spectrum (see Figure
7), but more complete. B-ions appeared as protonated
ions whereas the corresponding Y-ions contained so-
dium and potassium adducts. The presence of Na or
K in the Y-ions was almost certainly due to the
presence of a carboxyl group in the reducing terminal
Kdo moiety. Direct comparison of ESI-MS/MS spectra
from partially sodiated and potassiated doubly charged
precursor ions of the same species allowed us to easily
differentiate between B- and Y-ions. Protonated B-ions
showed identical masses in both spectra, such as at m/z
366.1 (B2) and 731.3 (B4). In contrast, singly charged
metalated Y-ions revealed a mass difference of 16 Da,
corresponding to the mass difference between K and
Na, i.e., Y5 and Y7 were observed at m/z 1143.3 and
m/z 1508.5 as sodiated ion and at m/z 1159.4 and 1524.5
as potassiated ions.
ESI-MS/MS proved especially useful sequencing
high molecular weight oligosaccharides. In one experi-
ment, a triply charged precursor ion with [M  2H 
Na]3 at m/z 814.613 was selected that corresponds to
an oligosaccharide species containing (LacNAc)3 plus
an additional GalNAc (A'5b5, M 2418.82 Da) (data not
shown). An abundant series of B-ion fragments was
present that was complete from B1 through B6 (m/z
204.1, 366.2, 569.2, 731.3, 934.4 and 1096.4), encompass-
ing what is clearly a linear polyLacNAc structure. The
carbohydrate molecule with the highest molecular
weight was detected for the [M  3H]3 at m/z 982.963
(M  2945.86, A'5b8). The ESI-MS spectrum of the
original oligosaccharide fraction is shown in Figure 9
Figure 7. Positive-ion MALDI-PSD spectrum of polyLacNAc
containing oligosaccharides. Precursors ions selected were (a)
[M  Na] at m/z 1874.0 (di-LacNAc) and (b) [M  Na] at m/z
2604.8 (tetra-LacNAc). Kdo* refers to anhydroKdo. Ion nomencla-
ture is according to that proposed by Domon and Costello [40].
Figure 8. ESI-MS/MS spectrum of doubly charged metalated
di-LacNAc containing oligosaccharide (a) [M  H  Na]2 at m/z
937.32 (M  1850.6 Da) and (b) [M  H  K]2 at m/z 945.32
(M  1850.6 Da). B-type fragment-ions appear as protonated
species whereas Y-type ions appear as metalated species. Kdo*
refers to anhydroKdo.
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(inset) and revealed a very weak signal at m/z 982.96
(z  3). ESI-MS/MS analysis of this isolated oligosac-
charide generated numerous Y- and B-ion fragments
that were consistent with a linear (LacNAc)5 terminal
structure. The most prominent peak of the spectrum at
m/z 731.3 was assigned as B4-ion (terminal di-LacNAc).
The corresponding counter-ion Y11-ion at m/z 1108.9
2
(M  2216.7) was also observed. Several other of these
ion-pairs helped to confirm the (LacNAc)5 structure,
including the B/Y-ion pairs at m/z 366.1/1291.02 [B2/
Y13
2 ], m/z 1096.4/1851.6 [B6/Y9], m/z 1461.5/1486.5
[B8/Y7], and m/z 913.9
2/1121.4 [B10
2 /Y5]. The B-ion
components of these ion pairs are formed by fragmen-
tation of GlcNAc-Gal glycosidic bonds and are presum-
ably stabilized by the nitrogen in the GlcNAc residue.
Although ESI-MS/MS spectra provided complete
sequences of the terminal LacNAc regions of all oligo-
saccharides that were isolated, a different approach was
needed to obtain sequence data on oligosaccharide
branches from low abundant LOS-glycoforms and/or
ones that contain sialic acid. In these cases, isolation of
the corresponding oligosaccharides was difficult, espe-
cially for those that contain sialic acid. Although nega-
tive-ion ESI-MS/MS of the O-LOS mixtures can yield
useful data, it is our experience that positive-ion ESI-
MS/MS of dephosphorylated O-LOS yields more abun-
dant molecular ions and more sequence information. To
obtain LOS-glycoforms that are more suitable to ESI-
MS/MS under positive-ion conditions, the O-deacy-
lated LOS glycoforms were treated with aqueous HF
(4 °C, 12 h) to remove PEA and phosphate. HF-treat-
ment of the O-LOS species at Mcalc 2721/2744 Da
(A'5b1) would be expected to cleave one phosphate and
0–1 PEA from the Kdo residue, and two phosphate
groups from the Lipid A moiety to yield a dephospho-
rylated O-LOS glycoform with an exact mass of Mcalc 
2481.0894. The corresponding tandem mass spectrum of
this glycoform was obtained by selecting the doubly
charged precursor ion at [M  2H]2  m/z 1241.531
(Mobs  2481.047, m  17 ppm); (spectrum not
shown). Although the Lipid A moiety is still present,
most fragment ions present in the MS/MS spectrum
were B- and/or Y-ions originating from the oligosac-
charide portion including an abundant B-ion (B1–4 at
m/z 204.1, 366.1, 569.2, 731.3) and Y-ion series (Y3–7 at
m/z 2279.3, 2116.9, 1913.9, 1751.7, and 1559.8). Together,
these ions clearly defined the non-reducing terminal se-
quence GlcNAc3Gal3GlcNAc3Gal3Hep. This ap-
proach, therefore, provided sufficient sensitivity and effi-
ciency to sequence an intact LOS without chemically
cleaving and separating the resulting oligosaccharide
from the Lipid A prior to mass spectrometric analysis.
To test the sensitivity of the ESI-MS/MS approach
for sequencing even larger and more labile O-LOS
species, we examined two sialylated glycoforms. As
mentioned earlier, when the H. ducreyi 35000hep
strain is grown on solid media, LOS terminating in
sialyl-LacNAc (A'5a1) and in sialyl-di-LacNAc (A'5b2a1),
are the major species formed (Figure 3b and 4). Tandem
mass spectrometry of the HF-treated O-LOS-glycoform
containing a single terminal sialyl-LacNAc moiety acid
(precursor-ion with [M  H  Na]2 at m/z 1296.530, M
 2569.061, m  17 ppm, data not shown) yielded
characteristic fragment ions such as Y-ions (Y37), and
B1 and B3-ions at m/z 292.1 and 657.2 (B3-18 ion at m/z
639.2), which gave structural proof that a terminal sialic
acid residue was added to the terminal LacNAc moiety.
The presence of the abundant sialylated di-LacNAc
species (A'5b2a1) was of considerable interest, as the
di-LacNAc species has been reported to be present in
wild type strains but not the sialylated counterpart [14].
To obtain unambiguous data for this sialylated di-
LacNAc glycoform, an ESI-MS/MS spectrum was re-
corded for the dephosphorylated O-LOS of the [M  H
 Na]2 at m/z 1479.082 (M  2934.166, m  24 ppm,
see Figure 10). Consistent with previous data, most
fragment-ions originated from the oligosaccharide moi-
ety. In particular, the B1 and B3-ions at m/z 292.1 and
657.3 (B3-18 ion at m/z 639.2) proved that sialic acid
was substituted on the terminal LacNAc acceptor. An
internal di-LacNAc fragment ion at m/z 731.3 and the
characteristic B5-ion at m/z 1022.4 were especially
abundant. In addition, fragment-ions at m/z 2164.7,
1873.6, 1508.5, 1346.4, and 1143.3 were assigned to
oligosaccharide fragments that had lost the Lipid A
moiety as well as one or terminal sugars (Figure 10,
inset).
Conclusions
In a previous study by our group [20], an H. ducreyi
heptosyltransferase-III knockout mutant was con-
structed from a prototype strain 35000 and reported to
synthesize a LOS that contained a series of unexpected
high mass glycoforms. Moreover, the masses of these
high mass LOS species were consistent with the forma-
tion of a series of polyLacNAc and corresponding
sialylated structures. At the time, the structural evi-
Figure 9. ESI-MS/MS spectrum of 5 LacNAc unit containing
oligosaccharide A'5b8. Selection of triply charged, protonated
precursor ion [M  3H]3 at m/z 982.963 (M  2945.86). Kdo*
refers to anhydroKdo. Ions marked with an asterisk are internal
ions.
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dence for these assignment was limited to mass and
immunochemical data and no sequence data was pre-
sented. In this study, we used a combination of exogly-
cosidase digestion and mass spectrometric techniques
(MALDI-MS, MALDI-PSD, ESI-MS, and ESI-MS/MS)
to provide structural proof for these novel glycoforms.
In addition, we have evaluated the various MS ap-
proaches for their overall suitability to analyze and
sequence low-abundance, high-mass glycolipids in
complex mixtures.
The combination of exoglycosidase digestion and
mass spectrometry were critical to defining these struc-
tures. With few exceptions, however, these two tech-
niques have not been used together in the analysis of
complex glycan mixtures [36, 37]. In our analysis, we
successfully employed up to four consecutive exogly-
cosidase digestion steps on LOS mixtures containing as
many as 15 species, and the mass shifts of the constit-
uent glycoforms could be easily followed to provide
information on anomeric centers, sugar types, and
linkages. The enzymes -galactosidase and -N-acetyl-
hexosaminidase, for example, are both highly specific
for -anomeric glycosidic bonds. In addition, -galac-
tosidase clearly favors hydrolysis of 1–6 and 1–4
linked Gal-GlcNAc over the corresponding (1–3)
bonds (relative hydrolysis rates, 100:75:1, respectively).
Together with the immunochemical data that indicated
the presence of terminal LacNAc epitopes, the precise
linkages, sugar types, and anomeric configurations
could be readily assigned.
The use of MALDI-MS and ESI-MS for the analysis of
bacterial lipooligosaccharides as well as other types of
glycans have been well established tools for molecular
weight and structure analysis. As we have previously
reported [9, 19], MALDI and MALDI-PSD can provide
data regarding molecular weight, phosphorylation
state, and heterogeneity on the Lipid A and oligosac-
charides portions of LOS. However, sequence-specific
ions for the oligosaccharide portion of LOS is best
obtained from the purified oligosaccharide after mild
acid hydrolysis. A core oligosaccharide substituted with
up to four repeating LacNAc disaccharides yielded
extensive, although somewhat weak, Y- and B-type
fragment ions. The tetra-LacNAc glycoform appeared
to be near or at the limit of MALDI-PSD sensitivity, as
higher masses or glycans substituted with sialic acid
did not yield sufficient fragments to assign the struc-
ture. In contrast, ESI-MS/MS on a quadrupole o-TOF
instrument proved especially efficient and sensitive
providing extensive fragments on the least abundant,
high-mass OS structures (up to five LacNAc repeats).
This capability was critical to obtain sequence infor-
mation on the unseparated LOS mixtures (after O-
deacylation and HF treatment).
The biological significance of these polyLacNAc
structures in the LOS of this H. ducreyi mutant strain is
unclear. This is the first time that a LOS containing a
polyLacNAc structure has been identified in bacteria.
Regardless of the precise function of these polyLacNAc
structures, or even whether they exist in wild-type
organisms, our data suggest that a biosynthetic path-
way is available to this pathogen that was previously
unknown. The observed polyLacNAc and sialylated
LOS analogs were present as relatively minor compo-
nents in a complex glycoform mixture. It is entirely
possible, however, that these polyLacNAc structures
could be the major forms expressed in the human host.
In N. gonorrhoeae, a shift to higher molecular weight
glycoforms containing 1-2 terminal LacNAc residues
was shown to occur after human challenge [38]. Similar
structures, if expressed by H. ducreyi under in vivo
conditions, would likely play important roles in allow-
ing the organism to survive and/or replicate. The
analysis of H. ducreyi recovered from the human chal-
lenge model may be able to confirm or disprove the
presence of polyLacNAc, although such an analysis will
be difficult because of the very low number of organ-
isms that are present in these lesions [39]. However,
should this polyLacNAc structural phenotype be stable
enough to allow for growth in primary culture after
human challenge, sufficient material should be obtain-
able. Our observation that H. ducreyi grown in liquid
media yields primarily non-sialylated polyLacNAc LOS
structures, while those that are grown on plates yield
sialylated LOS, may be a critical observation in terms of
a possible regulatory control of LOS sialylation. H.
ducreyi can adhere to a number of human cell types and
have been observed as large colonies, and, therefore
organisms grown on surfaces (i.e., solid media) may
mimic aspects of this in vivo adherent phenotype.
Overall, the data present here has provided new insight
into possible roles for LOS in the pathobiology of H.
ducreyi.
Figure 10. ESI-MS/MS spectrum of HF-treated O-deacylated
LOS A'5b2a1 containing terminal sialyl-(LacNAc)2. Selection of
doubly charged, protonated precursor ion with [M  H  Na]2
at m/z 1479.08 (M  2934.17 Da). Kdo* refers to anhydroKdo; Lipid
A* refers to the dephosphorylated di-N-acyl form generated after
hydrazine and HF treatment. Ions marked with an asterisk are
internal ions; ions marked with a pound sign (#) are background
ions.
733J Am Soc Mass Spectrom 2002, 13, 724–734 STRUCTURE OF POLYLACTOSAMINE-CONTAINING GLYCOFORMS
Acknowledgments
The authors wish to acknowledge the financial support of this
work by grants from the National Institutes of Health AI31254 (to
BWG) and AI30006 (AAC). Special thanks to Dr. Nancy Phillips
for helpful discussions. We also acknowledge Applied Biosystems
(Framingham, MA) for the generous support of the MALDI-TOF
instrumentation in our laboratory (to BWG).
References
1. Trees, D. L.; Morse, S. A. Clin. Microbiol. Rev. 1995, 8, 357–375.
2. Jessamine, P. G.; Ronald, A. R. Med. Clin. North Am. 1990, 74,
1417–1431.
3. Spinola, S. M.; Orazi, A.; Arno, J. N.; Fortney, K.; Kotylo, P.;
Chen, C. Y.; Campagnari, A. A.; Hood, A. F. J. Infect. Dis. 1996,
173, 394–402.
4. Centers for Disease Control and Prevention. Morbid. Mortal.
Weekly Rep 1998, 47, 1–24.
5. Ison, C. A.; Dillon, J. A.; Tapsall, J. W. . Lancet 1998, 351(Suppl.
3), 8–11.
6. Abeck, D.; Korting, H. C. Acta Dermato. Venereol. Suppl. 1991,
174, 5–20.
7. Alfa, M. J.; DeGagne, P. Microb. Pathog. 1997, 22, 39–46.
8. Gibson, B. W.; Campagnari, A. A.; Melaugh, W.; Phillips, N. J.;
Apicella, M. A.; Grass, S.; Wang, J.; Palmer, K.; Munson, R. S. J.
J. Bacteriol. 1997, 179, 5062–5071.
9. Gibson, B. W.; Engstrom, J. J.; John, C. M.; Hines, W.; Falick,
A. M. J. Am. Soc. Mass Spectrom. 1997, 8, 645–658.
10. Melaugh, W.; Phillips, N. J.; Campagnari, A. A.; Tullius, M. V.;
Gibson, B. W. Biochemistry 1994, 33, 13070–13078.
11. Melaugh, W.; Gibson, B. W.; Campagnari, A. A. J. Bacteriol.
1996, 178, 564–570.
12. Schweda, E. K.; Sundstrom, A. C.; Eriksson, L. M.; Jonasson,
J. A.; Lindberg, A. A. J. Biol. Chem. 1994, 269, 12040–12048.
13. Bozue, J. A.; Wang, J.; Tullius, M. V.; Gibson, B. W.; Munson,
J. R. S. J. Biol. Chem. 1999, 274, 4106–4114.
14. Schweda, E. K.; Jonasson, J. A.; Jansson, P. E. J. Bacteriol. 1995,
177, 5316–5321.
15. John, C. M.; Schneider, H.; Griffiss, J. M. J. Biol. Chem. 1999,
274, 1017–1025.
16. Kniep, B.; Schakel, K.; Nimtz, M.; Schwartz-Albiez, R.;
Schmitz, M.; Northoff, H.; Vilella, R.; Gramatzki, M.; Rieber,
E. P. Glycobiol. 1999, 9, 399–406.
17. Prieto, P. A.; Larsen, R. D.; Cho, M.; Rivera, H. N.; Shilatifard,
A.; Lowe, J. B.; Cummings, R. D.; Smith, D. F. J. Biol. Chem.
1997, 272, 2089–2097.
18. Heffernan, M.; Lotan, R.; Amos, B.; Palcic, M.; Takano, R.;
Dennis, J. W. J. Biol. Chem. 1993, 268, 1242–1251.
19. Sun, S. H.; Schilling, B.; Tarantino, L.; Tullius, M. V.; Gibson,
B. W.; Munson, R. S. J. Bacteriol. 2000, 182, 2292–2298.
20. Filiatrault, M.; Gibson, B. W.; Schilling, B.; Sun, S.; Munson,
R. S., Jr.; Campagnari, A. A. Infect. Immun. 2000, 68, 3352–3361.
21. Campagnari, A. A.; Spinola, S. M.; Lesse, A. J.; Kwaik, Y. A.;
Mandrell, R. E.; Apicella, M. A. Microb. Pathog. 1990, 8,
353–362.
22. Campagnari, A. A.; Wild, L. M.; Griffiths, G. E.; Karalus, R. J.;
Wirth, M. A.; Spinola, S. M. Infect Immun. 1991, 59, 2601–2608.
23. Tsai, C. M.; Frasch, C. E. Anal. Biochem. 1982, 119, 115–119.
24. Knecht, D. A.; Dimond, R. L. Anal. Biochem. 1984, 136, 180–184.
25. Apicella, M. A.; Griffiss, J. M.; Schneider, H. Methods Enzymol.
1994, 235, 242–252.
26. Johnson, K. G.; Perry, M. B. Can. J. Microbiol. 1976, 22, 29–35.
27. Westphal, O.; Jahn, K.In Methods in Carbohydrate Chemistry;
Whistler, R. L., Ed.; Academic Press Inc.: New York, 1965; 5,
83–91.
28. Helander, I. M.; Nummila, K.; Kilpelainen, I.; Vaara, M. Prog.
Clin. Biol. Res. 1995, 392, 15–23.
29. Spengler, B.; Kirsch, D.; Kaufmann, R. Rapid Commun. Mass
Spectrom. 1992, 6, 105–108.
30. Vestal, M. L.; Juhasz, P.; Martin, S. A. Rapid Commun. Mass
Spectrom. 1995, 9, 1044–1050.
31. Mohr, M. D.; Bornsen, K. O.; Widmer, H. M. Rapid Commun.
Mass Spectrom. 1995, 9, 809–814.
32. Phillips, N. J.; Apicella, M. A.; Griffiss, J. M.; Gibson, B. W.
Biochemistry 1992, 31, 4515–4526.
33. Harvey, D. J. Mass Spectrom. Rev. 1999, 18, 349–450.
34. Olsthoorn, M. M. A.; Haverkamp, J.; Thomas-Oates, J. E. J.
Mass Spectrom. 1999, 34, 622–636.
35. Harvey, D. J. J. Mass Spectrom. 2000, 35, 1178–1190.
36. Kuster, B.; Naven, T. J.; Harvey, D. J. J. Mass Spectrom. 1996, 31,
1131–1140.
37. Venkataraman, G.; Shriver, Z.; Raman, R.; Sasisekharan, R.
Science 1999, 286, 537–542.
38. Schneider, H.; Griffiss, J. M.; Boslego, J. M.; Hitchcock, P. J.;
Zahos, K. M.; Apicella, M. A. J. Exp. Med. 1991, 174, 1601–1605.
39. Spinola, S. M.; Wild, L. M.; Apicella, M. A.; Gaspari, A. A.;
Campagnari, A. A. J. Infect. Dis. 1994, 169, 1146–1150.
40. Domon, B.; Costello, C. E. Glycoconj. J. 1988, 5, 397–409.
734 SCHILLING ET AL. J Am Soc Mass Spectrom 2002, 13, 724–734
